DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
It's - 2 Myers - 2 Gregory Renza - 1 Renza - 1 Oppenheimer - 1 Jeff Jones - 1 Piper Sandler - 1 Edward Tenthoff - 1
Top related locs:
Bristol Mariana London England Britain Cambridge U.S New York
Top related orgs:
Bristol - 3 REUTERS - 2 Thomson - 2 Myers Squibb - 2 pharma - 1 RBC Capital Markets - 1 TRT - 1 Novartis - 1

Search resuls for: "Bristol's"


4 mentions found


☆ This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
  + stars: | 2024-05-23 | by ( Michelle Fox | ) www.cnbc.com   time to read: +7 min
RBC Capital Markets sees a $25 billion market opportunity for the space. The average analyst rating is hold, with 8% upside to the average analyst price target, according to FactSet. Eli Lilly has an average analyst rating of overweight and 8.3% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon AstraZeneca's one-year performanceAstraZeneca shares have an average analyst rating of overweight and nearly 6% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon Bristol-Myers Squibb's one-year performance
Persons: It's, Gregory Renza, Renza, Oppenheimer, Jeff Jones, Piper Sandler, Edward Tenthoff, Eli Lilly, Dan Lyons, Janus Henderson, Myers Squibb, William Blair, Matt Phipps, Jefferies, Andrew Tsai, They've, Janus Henderson's Lyons, Jones, Piper Sandler's Tenthoff, Myers Organizations: pharma, RBC Capital Markets, TRT, Novartis, Mariana Oncology, Janus, Janus Henderson Investors, Bristol, RayzeBio, Karuna Therapeutics, AstraZeneca, Fusion Pharmaceuticals, GlobalData's Pharma Intelligence, Pluvicto Locations: Mariana, Bristol
☆ Britain to invest 300 million pounds in AI supercomputing
  + stars: | 2023-11-01 | by ( ) www.reuters.com   time to read: +2 min
British Prime Minister Rishi Sunak delivers a speech on AI at Royal Society, Carlton House Terrace on October 26, 2023 in London, England. Funding for the "AI Research Resource" will be increased to 300 million pounds ($363.57 million) from a previously announced 100 million pounds, the government said at an AI safety summit aimed at charting a safe way forward for the rapidly evolving technology. "Frontier AI models are becoming exponentially more powerful," British Prime Minister Rishi Sunak said on social media platform X. "This investment will make sure Britain’s scientific talent have the tools they need to make the most advanced models of AI safe." The machines, which will be running from summer next year, will be used to analyse advanced AI models to test safety features, as well as to drive breakthroughs in drug discovery and clean energy, the government said.
Persons: Rishi Sunak, Peter Nicholls, Bristol's, Kylie MacLellan, Kirsten Donovan Organizations: British, Royal Society, Carlton, Terrace, REUTERS, Nvidia, Hewlett Packard Enterprise, Dell, SME, Thomson Locations: London, England, Britain, Cambridge, Bristol
☆ Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal
  + stars: | 2023-10-09 | by ( Michael Erman | ) www.reuters.com   time to read: +3 min
REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsOct 8 (Reuters) - Bristol-Myers Squibb (BMY.N) on Sunday said it will acquire cancer drugmaker Mirati Therapeutics (MRTX.O) for up to $5.8 billion, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade. Bristol will pick up Mirati's portfolio drugs that target the genetic drivers of specific cancers including its lung cancer drug, Krazati, which was approved in December. The company said that it will buy Mirati for $58 per share in cash, or around $4.8 billion. Mirati has around $1.1 billion in cash on hand, so "we're paying essentially $3.7 billion enterprise value...we think with that we've gotten a very attractive deal," Lenkowsky said. Last year, Bristol acquired drug developer Turning Point Therapeutics for $4.1 billion in cash to help bolster its arsenal of cancer drugs.
Persons: Bristol Myers, Dado Ruvic, Adam Lenkowsky, Mirati, we've, Lenkowsky, Chris Boerner, Giovanni Caforio, Boerner, Lavanya Ahire, Lisa Shumaker, Diane Craft, Andrea Ricci, Michael Perry Organizations: Bristol, Bristol Myers Squibb, REUTERS, Myers Squibb, Therapeutics, U.S . Food, Drug Administration, Bristol Myers, Thomson Locations: Bristol, U.S, New York
☆ Cramer's Lightning Round: Super Micro Computer is not a buy
  + stars: | 2023-05-30 | by ( Julie Coleman | ) www.cnbc.com   time to read: +3 min
Stock Chart Icon Stock chart icon Bowlero's year-to-date stock performance. Stock Chart Icon Stock chart icon Corteva's year-to-date stock performance. Stock Chart Icon Stock chart icon Telus's year-to-date stock performance. Stock Chart Icon Stock chart icon Super Micro Computer's year-to-date stock performance. Stock Chart Icon Stock chart icon Upstart's year-to-date stock performance.
Persons: Myers, Smith, Neidorff, That's, It's Organizations: Bristol, Myers Squibb, Telus, Mobile, Verizon, Carrier Locations: California, Bristol, Myers, Europe
0 next >>
Total: 4